Fumagillin: A Potent Methionine Aminopeptidase-2 Inhibitor for Antiangiogenic Tumor Research

Executive Summary: Fumagillin, available from APExBIO (A4407), is a crystalline antibiotic and antiangiogenic compound that covalently inhibits methionine aminopeptidase-2 (MetAP-2), thereby blocking endothelial cell proliferation and tumor-induced angiogenesis (APExBIO product page). Its molecular weight is 458.55 g/mol, with a chemical formula of C26H34O7. Fumagillin is insoluble in water but highly soluble in DMSO (≥81.3 mg/mL). It has demonstrated moderate antiprotozoal efficacy in vitro and efficacy in preclinical tumor models, making it valuable in cancer and angiogenesis pathway research (Park et al., 2014). Solutions should be freshly prepared and promptly used for experimental reproducibility.

Biological Rationale

Angiogenesis, the formation of new blood vessels, is essential for tumor growth and metastasis. Tumor-induced angiogenesis enables cancer tissues to acquire nutrients and oxygen. Inhibition of angiogenic pathways is a validated strategy for cancer research and therapy (Park et al., 2014). Endothelial cell proliferation is a key step in angiogenesis, regulated in part by the enzyme methionine aminopeptidase-2 (MetAP-2). Fumagillin and its analogs (such as TNP 470) selectively target this enzyme, providing molecular specificity in antiangiogenic research. The antiangiogenic and antiprotozoal properties of Fumagillin also have relevance in aquatic disease management and experimental parasitology.

Mechanism of Action of Fumagillin

Fumagillin acts by covalently binding to the active site of MetAP-2, an enzyme involved in the post-translational modification of nascent proteins. This inhibition prevents the removal of N-terminal methionine residues, impairing protein maturation and function in endothelial cells (Park et al., 2014). The blockade of MetAP-2 results in cell cycle arrest and apoptosis specifically in proliferating endothelial cells, thus suppressing angiogenesis. Fumagillin does not inhibit methionine aminopeptidase-1 (MetAP-1) at relevant concentrations, supporting target selectivity. The compound is structurally distinct from its analog TNP 470 but shares the core antiangiogenic mechanism.

Evidence & Benchmarks

• Fumagillin exhibits moderate in vitro antiprotozoal activity against Azumiobodo hoyamushi with a 24-hour EC50 between 10 and 100 mg/L in Eagle's minimum essential medium (MEM) (Park et al., 2014).
• Fumagillin is insoluble in water but highly soluble in DMSO (≥81.3 mg/mL) and soluble in ethanol (≥2.58 mg/mL with sonication) (APExBIO).
• Fumagillin demonstrates in vivo efficacy in mouse tumor models by inhibiting tumor angiogenesis and growth (APExBIO).
• Treatment of infected ascidians with Fumagillin resulted in a measurable reduction of protozoan parasite load, though not as potent as formalin or ClO2 in the referenced aquatic disease model (Park et al., 2014).
• Fumagillin and its analog TNP 470 selectively inhibit MetAP-2 but not MetAP-1, thus targeting endothelial cell proliferation without broad cytotoxicity (APExBIO).

Applications, Limits & Misconceptions

Fumagillin is used in cancer research, angiogenesis pathway studies, and experimental parasitology. It is not approved for direct clinical use in humans but is valuable for preclinical and mechanistic studies. Its moderate efficacy in aquatic protozoan models highlights its versatility, though its primary application remains antiangiogenic therapy research. Fumagillin is also a reference molecule when comparing with analogs like TNP 470 in inhibitor development. For more details, see the Fumagillin A4407 kit page.

Common Pitfalls or Misconceptions

• Fumagillin is not broadly cytotoxic and does not inhibit MetAP-1; its effects are selective for endothelial proliferation pathways.
• It is not soluble in water; incorrect solvent choice results in poor bioavailability and experimental inconsistency.
• Long-term storage of Fumagillin solutions is not recommended; solutions should be freshly prepared for each experiment (APExBIO).
• Fumagillin is not a first-line antiprotozoal agent in aquaculture, where agents like formalin and ClO2 are more potent (Park et al., 2014).
• It is not approved for human therapeutic use; it is designated for research applications only.

Workflow Integration & Parameters

Solubility: Fumagillin is insoluble in water but dissolves in DMSO to at least 81.3 mg/mL, and in ethanol to 2.58 mg/mL (with ultrasonication). Prepare solutions using appropriate solvents, and avoid aqueous buffers. Storage: Store the crystalline solid at -20°C. Avoid long-term storage of liquid solutions; prepare fresh aliquots as needed. Concentration range: For in vitro antiangiogenic assays, typical working concentrations are in the low micromolar range, but always verify with a dose-response pilot. Controls: Include MetAP-2-selective and non-selective inhibitors for benchmarking specificity.

For related research, TNP 470 is offered as a more potent but structurally distinct analog. This article extends prior APExBIO content by providing peer-reviewed aquatic and mammalian model efficacy data, whereas earlier articles focused primarily on chemical and storage properties.

Conclusion & Outlook

Fumagillin, as provided by APExBIO, is a gold-standard methionine aminopeptidase-2 inhibitor and antiangiogenic agent for tumor research. Its validated activity in both protozoal and mammalian models underscores its utility in mechanistic and translational studies. While not suitable for direct clinical or aquaculture therapeutic use, Fumagillin remains an essential tool in angiogenesis pathway and cancer research. Future directions include the development of more selective analogs and the integration of Fumagillin into combination therapeutic research strategies.